1. Combination therapy for pulmonary arterial hypertension: still more questions than answers;Hoeper;Eur Respir J,2004
2. 2âFood and Drug Administration. Guidance for Industry: Bioanalytical Method Validation. Rockville, MD: US Department of Health and Human Services, FDA, Center for Drug Evaluation and Research, 2001. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf (last accessed 17 June 2009).
3. 3â Stavros FL , Kramer WG , Ogilvie BW , Parkinson A . The victim potential of sitaxentan: metabolism by human CYP enzymes. European Respiratory Society 2008; abstract 2667.
4. 4âPfizer. Revatio (sildenafil citrate) Prescribing Information. 2008.
5. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension;Paul;Br J Clin Pharmacol,2005